A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine

Pharmacopsychiatry
M MauriG B Cassano

Abstract

The aim of this study was to evaluate the efficacy of a psychoeducational program (PEP) for weight control in patients who had experienced an increase of body weight during treatment with olanzapine. Eligible patients were randomised to the PEP (Group 1) or to no intervention (Group 2) and continued on olanzapine. After 12 weeks, the PEP was also started in Group 2 and continued in Group 1, up to week 24. Body weight was measured every month. Other measures included quality of life, and change in plasma glucose and lipids levels. Patients in Group 1 (n=15) had a mean weight loss of 3.6 kg at week 12 and 4.5 kg at week 24 (p<0.01 at both times, p<0.01 between groups at week 12), while those in Group 2 (n=18) had no changes at week 12 and a significant weight loss at week 24 (-3.6 kg from week 12, p<0.01). Changes of BMI paralleled those of body weight. Quality of life (Q-LES-Q-SF categorisation) and functioning (GAF) significantly improved in the total population at endpoint (p<0.01). No significant changes were observed in fasting glucose and lipid profile, while insulin levels significantly decreased from baseline to endpoint in both groups (p<0.05). HOMA index and hepatic insulin sensitivity improved, too. Patients with incre...Continue Reading

Citations

Apr 13, 2011·The International Journal of Behavioral Nutrition and Physical Activity·Nick VerhaegheLieven Annemans
Jan 29, 2011·Primary Care Companion to the Journal of Clinical Psychiatry·Kornelia GillhoffWaldemar Greil
Jul 26, 2008·Postgraduate Medicine·Leslie Citrome, Betty Vreeland
Jul 1, 2010·Expert Review of Neurotherapeutics·Lawrence Maayan, Christoph U Correll
Jul 17, 2009·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Tamás TreuerSusanna Holt
Jul 14, 2011·Journal of Psychiatric and Mental Health Nursing·N VerhaegheL Annemans
Nov 11, 2011·CNS Neuroscience & Therapeutics·Karla M de AlmeidaBeny Lafer
Nov 5, 2016·The British Journal of Psychiatry : the Journal of Mental Science·Scott B TeasdaleBrendon Stubbs
Jul 26, 2019·JBI Database of Systematic Reviews and Implementation Reports·Doreen MucheruLesley MacDonald-Wicks
Sep 9, 2019·Health Promotion Journal of Australia : Official Journal of Australian Association of Health Promotion Professionals·Doreen MucheruLesley MacDonald-Wicks
Aug 30, 2018·The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association·Catana BrownMarian Arbesman
Dec 15, 2010·The Cochrane Database of Systematic Reviews·Anitha MukundanGary Remington
Dec 18, 2013·Santé mentale au Québec·Marie-Ève BélangerChristian Shriqui

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.